Vanstar Announces the Sale of the Assets of Its Squidbet Platform
Momentum Public Relations
Press Release: November 26, 2019
The management of Vanstar Mining Resources Inc. (“Vanstar”) announces, following its press release of July 30, 2019, the signing of a letter of intent for the sale, in the form of an assignment, assets, all rights and interests of its Squidbet social platform to 56 Acquisitions Inc. (“56”), a Vancouver-based corporation.
Through this non-related party transaction, 56 will acquire 100% of the assets related to the Squidbet Project for $ 500,000 payable by the issuance of common shares (each, a “56 Share”) of 56 at a deemed price of $ 0.05 per Share 56.
The closing of the transaction is subject to certain conditions including satisfactory due diligence, the signing of a definitive asset purchase agreement, and the closing of a private placement of a minimum of $ 750,000 of units (each, a “56 Unit”) from 56 at $ 0.05 per unit with Vanstar’s interest for up to $ 250,000. Each “56 Unit” is composed of a “56” share and “56” warrant with an exercise price of $ 0.10 for a term of 24 months.
Closing of the transaction is expected no later than December 31, 2019. 56 expects to change its name to Focus Solutions Ventures at closing.
“We are very pleased to complete this transaction with 56 Acquisitions. Vanstar will now be able to fully refocus its activities in the mining sector, “said Guy Morissette, CEO of the company.
Depending on the regulations and authorizations to be obtained, it is expected that the shares obtained by this transaction will, in whole or in part, be redistributed as dividends to “Vanstar” shareholders at a later date.
The TSX Venture Exchange and its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) assume no responsibility for the adequacy or accuracy of this release.
About Nelligan Project
With respect to the Nelligan project, the company’s management is preparing a series of meetings with the Canadian financial community. Following an initial NI 43-101 assessment, Vanstar management recently released (October 22, 2019) an inferred resource of close to 3.2 million ounces of gold. This project, developed in collaboration with IAMGOLD Corporation (51%) and Vanstar (49%) has the potential to become one of the largest gold projects in Canada. Everything remains open both laterally and deeply.
In the coming months, additional metallurgical testing will be conducted to provide additional information on the metallurgical recovery of the various mineralization zones including the mineral resources of the Nelligan gold deposit and to help optimize the parameters of the treatment chart.
Drilling program planning is underway and will include a number of objectives including additional definition drilling to improve the categorization of resources and convert inferred resources to indicated resources as well as to assess the potential for increasing resources in these areas. deeper parts of the deposit and assess the extent of the resource along an assumed gold corridor of approximately 4 kilometers.
Regional exploration will also focus on defining and testing other priority exploration targets on the property.
Sources :
Guy Morissette, CEO
819-763-5096
Gary Claytens, VP – Western Corporate Development
604-761-3233
- Published in Mining, News Home, Technology, Vanstar Mining
ATYPICAL JUNIOR BUCKS THE VENTURE TREND
Canada Cobalt (TSXV: CCW; OTC, CCWOF)
October 17, 2019
The Venture has been hit hard since the middle of September, but there’s one company whose stock price has actually jumped more than 30% during that time. Last year it was featured on “The National” on CBC and the stock actually quadrupled in value in less than three months while the Venture was also slumping.
What’s so different about this company that it would be able to attract such positive media attention and outperform the market so significantly over lengthy periods? And why are its prospects now considered to be better than ever?
Unique Company Grows On A High-Grade Focus
Canada Cobalt (TSXV: CCW; OTC, CCWOF) is the company we’re referring to. Apart from having a technological solution (Re-2OX Process) to a longstanding environmental issue of arsenic-rich ores in a broad district of Northern Ontario known as the birthplace of Canadian hard rock mining, Canada Cobalt has separated itself from the rest of the junior resource sector due to its multiple near-term revenue streams ranging from high-grade silver recovery from its Castle mine and property to “urban mining” of high-grade gold and other metals from printed circuit boards. In several ways, CCW is racing down the same path that Agnico Eagle used many years ago in the Northern Ontario Silver-Cobalt Camp as a springboard to become the corporate giant it is today in the mining sector. In fact, CCW’s Castle mine was a cornerstone of Agnico Eagle’s success in the district throughout the 1980’s.
Grade is King. In Canada Cobalt’s world, drill results can be in the tens or even hundreds of ounces per ton, cobalt assays exceed the global average by orders of magnitude, and planned “urban mining” of printed circuit boards could yield gold in the ounces (not grams) per tonne.
Transformational Deal
Canada Cobalt is one of the most exciting opportunities we see in the market right now because it has so many different levers it can pull to generate interest and build shareholder value, especially after the October 10 announcement of a binding LOI to acquire the only facility in Canada’s silver-cobalt heartland that combines bullion pouring, bulk sampling, commercial assaying and e-waste processing. It’s located in the historic town of Cobalt, immediately next to a rail line and just a 1-hour drive from the Castle mine in Gowganda.
The binding LOI to acquire privately-held PolyMet Resources Inc., on very favorable terms, is truly a “game changer” for CCW. The deal creates a robust cash flow model and solidifies the company as the vertically integrated leader of a mining and exploration district that’s making a powerful comeback as bull markets ramp up in silver and gold, while the district’s potential as an ethical source of cobalt has drawn a lot of attention as the electric vehicle revolution intensifies.
CCW Scores Big On Castle Mine Waste Material
CCW Highlights:
There are multiple moving parts to this intriguing story, so here’s a quick bullet point summary of what’s unfolding now:
- Canada Cobalt has just poured its first silver bars in a proof-of-concept test ahead of a significant ramp-up that will officially begin with the pouring of a 1,000-ounce silver dore bar planned for later this month;
- Owning and advancing a high-grade past producing underground mine such as Castle, with historic tailings, puts Canada Cobalt in a unique position at this early stage of the silver bull market – tailings are being targeted for significant recovery of high-grade silver;
- The PolyMet facility, a shrewd deal completed for only $650,000 (half cash and half stock), comes with 4 profit centers: 1) Bullion pouring, which CCW is starting already; 2) Bulk sampling; 3) Commercial assaying; and 4) E-waste processing;
- The PolyMet facility becomes the home for Canada Cobalt’s proprietary and environmentally friendly Re-2OX Process which has allowed CCW to become the first company during the battery arms race to produce a high-purity cobalt sulphate product from its own mineralized material;
- PolyMet recently produced a ton of shredded printed computer circuit boards in a trial run that graded just over 7 oz per ton Gold, 2 oz per ton Palladium, 30 oz per ton Silver and 11% Copper, verified by a smelter in Chicago. That’s a phenomenal value of $15,000 per tonne!
- “Urban mining” has the potential to become a major new business for the PolyMet operation, under the umbrella of CCW and where it will also host its Re-2OX Process – check out ETI and MWX which have a combined market cap of around $130 million.
- Phase 2 underground drilling has commenced at Castle to build on stellar 2018 results such as 2 ounces per ton silver, 0.67% cobalt and 3.8 g/t gold over half a metre within a broader 5.51-m core length averaging 2,620 g/t silver (76.4 ounces per ton) in CA-18-02;
- The best place to find a new mine is near an old mine, and Canada Cobalt has exceptional discovery potential immediately east of the Castle mine (and two other past producers) where the company has drilled into gold and very high-grade silver.
Canada Cobalt has wisely protected its share structure in recent years, unlike its neighbors in the Northern Ontario Silver-Cobalt Camp, and has just under 84 million shares outstanding with no significant warrant overhang. Management and personnel have extensive experience in the region, going back decades, and have smartly executed on a broad vision for CCW that was laid out well before a major rush into the district by other companies beginning in 2016.
Significantly, Canada Cobalt has all the ingredients and potential to continue to clearly distinguish itself as a very different type of company in the junior resource sector.
- Published in Canada Cobalt Works, Mining, News Home, Technology
Sirona Biochem Appoints Chinese Lawyer Jason Tian to its Board of Directors
Momentum Public Relations
Press Release: June 12, 2019
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the “Company“) announces that Mr. Jason Tian will be joining its Board of Directors. Jason Tian is a Senior Partner at Landing Law offices based in Shanghai, China. Jason has been working with Sirona since 2018 representing the Company at strategic partnering meetings in China and France.
Jason Tian has been providing legal services to international clients since 2007 and has worked in top firms in China such as Beijing Zhonglun, Beijing Zhongyin, Beijing Dacheng and is now a Senior Partner of Shanghai Landing Law Offices. He also worked as senior legal translator in UK-based firm, Clifford Chance LLP, before starting his legal career.
Shanghai Landing Law Offices is a full-service law firm with headquarters in Shanghai, China. Lawyers at Landing provide full-service to clients in industries such as healthcare and pharmaceuticals as well as consumer retail in China. Landing has several domestic branches and overseas branches in the United States, India, Singapore, Indonesia, Bangladesh, Philippines and Cambodia.
“Sirona’s management team has developed an excellent working relationship with Jason. His legal knowledge and extensive network in the Chinese business community are proving to be tremendous assets to Sirona”, reports Sirona Biochem’s CEO Dr Howard Verrico.
The company also announces Casper Bych has resigned from Sirona’s Board of Directors.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law. The appointment of Jason Tian to the BOD is subject to exchange approval.
SOURCE Sirona Biochem Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2019/12/c2009.html
Contact:
regarding this press release, please contact: Jonathan Williams, Managing Director, Momentum PR, Phone: 1.450.332.6939, Email: jwilliams@momentumpr.com
- Published in Business, Life Sciences, News Home, Sirona Biochem, Technology
Mondias announces the results of its annual meeting
Momentum Public Relations
Press Release: June 11, 2019
Mondias Naturals Inc. (“Mondias” or the “Company”) (TSXV: NHP) is pleased to announce the results of its annual general and special meeting of shareholders (the “Meeting”), which was held yesterday in Montreal, Quebec. All of the nominees listed in the Company’s management information circular dated May 6, 2019, were re-elected as directors.
“This has been a very good first six months for Mondias as a newly listed public company,” said Jean-Philippe Gravel, President and Chief Executive Officer of Mondias. “Our proprietary CELEXT07 bio-defense stimulant plant extract is attracting increasing interest from large players in the agricultural, horticulture and cannabis industries. Our consumer health products sector is also progressing as expected, as we are preparing to launch a new line of sleeping aids products for the second part of 2019. These initiatives, along with others planned for later in the year, will enable Mondias to generate growth and new opportunities in 2019.”
“The Board is pleased with the results obtained to date and is strongly committed in helping Mondias to pursue its strategic growth plan. Our Board has the market expertise and skill set needed to guide the Company in creating value for our shareholders,” added Mr. André Rancourt, Executive Chairman of Mondias.
A total of 43 shareholders were represented in person or by proxy at the Meeting, holding 42,663,175 shares, or 67.57% of Mondias’ issued and outstanding shares.
Detailed results of the vote for the election of directors are set out below:
Nominee |
Votes |
% |
Votes |
% |
André Rancourt |
42,648,175 |
99.96% |
15,000 |
00.04% |
Frank Palantoni |
42,648,175 |
99.96% |
15,000 |
00.04% |
Bertrand Venne |
42,648,175 |
99.96% |
15,000 |
00.04% |
Michel Timperio |
42,648,175 |
99.96% |
15,000 |
00.04% |
Louis Doyle |
42,648,175 |
99.96% |
15,000 |
00.04% |
All other matters presented for shareholder approval at the Meeting were approved, as follows:
- Appointment of UHY McGovern Hurley LLP, Chartered Accountants, as auditors of the Company for the coming year and authorization of the directors to establish their remuneration;
- Amendment and ratification of the Company’s existing stock option plan; and
- Granting of stock options to purchase up to an aggregate of 3,200,000 common shares under the amended rolling option plan.
About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence-based botanical products for the health-care, bio-agriculture and organic markets. The Company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. Mondias is also developing botanical-based specialty fertilizers for use on household plants, lawns and golf courses and in urban gardens, nurseries and greenhouses, in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit: www.mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Business, Life Sciences, Mondias Natural, News Home, Technology
Mondias CELEXT07 latest test results confirm effective suppression of grey mould on hops
Momentum Public Relations
Press Release: May 16, 2019
Mondias Naturals Inc. (“Mondias” or the “Company”) (TSXV: NHP) is pleased to announce the results from research on the use of its proprietary CELEXT07 bio-defense stimulant plant extract on hops plants, conducted in collaboration with McGill University.
Global hops production is expected to grow by 3.3% to 122,767 metric tons in 2019 (Source: IHGC – Economic Commission Summary Reports, April 26, 2019). Hops production in the United States alone reached a record high of US$618 million in 2017, up 24% from US$498 million in 2016 (Source: U.S. Department of Agriculture). The global hops market is driven by increasing demand for hops in alcoholic beverages, medicinal drugs and cosmetic formulations. Over the next five years, increased demand for various flavours in beer such as pilsner or lager and the rise in popularity for hop-based craft beer are major factors that will significantly fuel the growth of the global hops market (Source: Persistence Market Research).
The objective of the current series of tests was to measure CELEXT07’s efficacy in suppressing and preventing diseases on hops plants. Hops is a genus belonging to the same taxonomic family as cannabis. Mondias’ latest experiments on cannabis and hops served as proof-of-concept of the efficacy of the Company’s botanicals in plant protection and increasing plant survival by eliciting induced resistance.
Summary of the test results:
- Foliar applications of CELEXT07 bio-defense stimulant extract were very effective in suppressing grey mould (caused by Botrytis cinerea) infections on hops, with decreases of 86% in disease severity and 67% in disease incidence.
- A scheduled dose split over three days for the soil drench application of CELEXT07 also proved effective for the prevention/suppression of grey mould on hops, with decreases of 31% in disease severity and up to 50% in disease incidence.
- Foliar and soil drench application of CELEXT07 did not have any phytotoxic effect on hops.
“These latest results continue to confirm that CELEXT07 is very effective in suppressing and preventing a wide range of fungal and bacterial pathogens, and has applications in more than one large market,” said Jean-Philippe Gravel, Chief Executive Officer of Mondias. “As mentioned in our last release, Mondias has secured the production capacity needed to meet demand from potential clients. CELEXT07 is ready to market and we are presently looking at selling our product through various sales channels and markets, including the agriculture, horticulture, cannabis and hops markets.”
With post-harvest losses of one-third of the food produced worldwide for human consumption (Gastavsson et al., 2011) and annual economic losses of $10 billion to $100 billion worldwide due to grey mould and powdery mildew (L. Hua et al., 2018), the market potential for CELEXT07 is considerable.
About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence-based botanical products for the health care, bio-agriculture and organic markets. The company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. Mondias is also developing botanical-based specialty fertilizers for use on household plants, lawns and golf courses and in urban gardens, nurseries and greenhouses, in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit: www.mondias.ca
- Published in Business, Life Sciences, Mondias Natural, News Home, Technology
MedX signs DermSecure distribution deal with CBD Vida
Momentum Public Relations
Press Release: April 9, 2019
MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that it has signed an Exclusive Distribution Agreement with CBD Vida (“Vida”), to launch a comprehensive, ease-of-access skin scanning/assessment program throughout Brazil, using MedX’s DermSecureTMTelemedicine platform.
This exclusive distribution agreement is a natural progression of the earlier Memorandum of Understanding with Vida “because their reach in the Brazilian marketplace is robust and extensive,” said Scott Spearn, President & CEO of MedX. Mr. Spearn said that Vida has agreed to pay for all regulatory, marketing and distribution expenses related to the launch. Mr. Spearn also noted that the agreed performance levels on the part of Vida further reinforce their commitment to the commercial success of this agreement.
“Vida is 100% committed to this innovative screening platform. There are almost 212 million Brazilian people, where skin cancer is the most common form of cancer,” said Camata Candello, Vida’s CEO. There were over 100,000 cases of skin cancer diagnosed in Brazil between 2016 and 2017, and almost 6,000 were melanomas, the most aggressive form of the disease that has a high mortality rate. “This cancer does not need to be lethal and can be prevented through early detection. I believe this is a game changer. Brazil is a huge market opportunity for us,” continued Mr. Candello.
“We are always looking for solutions that are innovative and meaningful to invest in; as well they must have a major impact on the Brazilian people we serve. I can genuinely say that MedX’s DermSecureTM meets those criteria, and then some,” said Camata Candello.
“MedX’s DermSecure TM is a perfect solution for early detection of skin cancer,” he said. “We are deeply aligned with the largest distributors of hospital equipment in Brazil, we will be distributing throughout the national territory of Brazil, offering MedX’s rapid skin assessment technology to Public and Private Hospitals, Medical Clinics, Pharmacies, Dermatologists and Oncologists. We believe this technology will have a major impact on public health, and as such have implemented a marketing plan to provide the equipment to Brazil’s public health network for a fee in order to speed the rate of deployment throughout Brazil,” stated Camata Candello, Vida’s CEO.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
About CBD Vida
The founders of CBD Vida Canada, combined with their CBD Vida LTDA partners in Brazil, form a partnership that brings decades of professional business development, training and experience. CBD Vida LTDA’s business relationships in Brazil are extensive and cover pharmaceuticals, medical clinics, and pharmacies, legal, regulatory, governmental, and private industry. These relationships provide a synergy between Brazil & Canada that will ensure expedited market entry for this life saving solution.
The partners understand the importance of Brazil on the world market, with it being the second largest importer of medical devices in the world. CBD Vida’s relationship with MedX and their rapid skin assessment solution, combined with their corporate & business experiences, will give the Brazilian population an opportunity to dramatically reduce the mortality rate currently being experienced by late the late detection skin cancer. CBD Vida LTDA has the capability and commitment to open the Brazilian market rapidly and help our fellow Brazilians with this preventable cancer.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
- Published in Life Sciences, MedX Health Corp., News Home, Technology
Mondias Completes Characterization of CELEXT07 that Confirms Its Biostimulant and Antifungal Capabilities and Expands Its Global Market Potential
Momentum Public Relations
Press Release: February 12, 2019
Mondias Naturals Inc (“Mondias” or “NHP“), (TSXV: NHP), announces that the research collaboration with McGill University has led to the identification of CELEXT07 signatory metabolite compounds, antibiotic properties and functional roles in plant physiology. This will lead to the development of several commercial products to meet emerging needs in bio-agricultural and organic markets and offer new chemical free solutions for the cultivation and food storage industries.
The chemical classes of compounds identified in the CELEXT07 extract confirms the botanical agent’s properties associated with plant defense against biotic stress by boosting the plant’s resistance as well as a biostimulant effect on growth. The identification of these compounds supports the previous research demonstrating CELEXT07’s biostimulant and antifungal protective and treatment properties.
Mr. Jean-Philippe Gravel, CEO of Mondias Naturals stated, “These results validate Mondias’ strategy to develop natural products for agricultural markets including post-harvest sub-markets. The CELEXT07 botanical extract will make a significant contribution to the bio-agricultural and organic markets and allow growers to offer horticultural products grown with no chemical agents. We are excited by this advancement since CELEXT07 is an eco-friendly alternative to synthetic fungicides.”
Postharvest diseases caused by storage fungi are responsible for the estimated loss of about 20 to 25% of harvested fruits and vegetables, and will certainly affect Canada’s new cannabis industry. Some fungi may produce mycotoxins that can cause toxicity to both animals and humans. Mycotoxin contaminations can occur in the field and greenhouse, before and after harvest, and also during post-harvest activities and storage. Mondias has been developing its CELEXT07 products to help prevent fungal growth on plants through its proven ability to increase plants’ defense system.
As previously reported in its December 5, 2018 news release, CELEXT07, when used as a soil drench agent, significantly reduced lesions caused by fungi on two greenhouse growing plants, tomato and lettuce, and significantly reduced lesions on detached leaves. Mondias has been expanding its research activities to target food and crop storage. Mr. Jean-Philippe Gravel, CEO of Mondias Naturals stated, “These results suggest that CELEXT07 botanical extract may become a low-risk solution to the new Canadian and USA cannabis agricultural industries.”
The market potential for CELEXT07 is considerable considering that these infections result in annual economic losses between $10 billion to $100 billion worldwide (L. Hua et al. 2018) and that about one-third of the food produced worldwide for human consumption is lost after harvest (Gastavsson et al., 2011).
About Mondias Natural Products Inc. Mondias specializes in the commercialization and development of evidence based botanical products for the health care, bio agriculture and organic markets. The company is already selling both oral and topical botanical agents to help manage unmet medical needs through Holizen Laboratories, one of its divisions. Mondias is also developing botanical based specialty fertilizers for use on household plants, urban gardens, lawns, golf courses, nurseries or greenhouses in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit: mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Business, Life Sciences, Mondias Natural, News Home, Technology
GROWPACKER – the next Amazon of cannabis?
GROWPACKER; THE NEXT AMAZON OF CANNABIS?
What could Amazon possibly offer to make them even more successful? Imagine they offered the manufacturing, branding, packaging and total distribution of every one of their client’s products.
Well that’s what California based GrowPacker does; except they do it for anything and everything related to the cannabis industry. With regards to everything I mean; non-alcoholic beverages, carbonated and non-carbonated beverages, water, candies, chocolate bars, brownies, cookies, creams, lotions, massage oils, vape oils, pre-rolls, flower and the list goes on…
Growpacker clients provide them with their cannabis and preferred product parameters, including product specs and with that information Growpacker turns it into a finished ingestible and edible product. Because let’s face it, if your still invested in cannabis stocks that don’t produce eatables, start smoking your profits away because you missed the boat.
On top of converting your THC and CBD into anything infused, Growpacker will take care of formulations, lab testing, packaging and; even the total distribution and transportation of your product. They have a turn key formula with all the required licenses to boot! And to make this even more delicious, the competitors are far behind. Growpacker was one of the first to begin this process and therefore have acquired all, I mean all, the necessary licenses to make this a growers dream come true. Currently Growpacker has +450 clients in the pipeline and nearly 100 that have started the on-boarding process for production with upwards of 10 inquires per day. If only all start-ups could be so fortunate…
Another satisfying point about Growpacker is that they do what they say. By the end of 2018 they said that they would have all their licences and they did. They also said that they are working on a high-profile brand relationship with THC infused beer start-up, Ceria Beverages Company, and it was solidified.
Speaking of Ceria, let’s look at the advisory board and shareholders of Growpacker. Keith Villa, the original founding member of Blue Moon Brewery, America’s #1 craft beer with annual revenue exceeding $250M and brand value of over $1B now owned and operated by MillerCoors, is a special advisor and shareholder to the company. He is also the one spearheading Ceria.
Furthermore, the special advisory board is made up of InterContinental Beverage Capital; (IBC) founders Joe Messina, Stephen F. Horgan and Doug Christoph who have all held top executive positions at Coca Cola and MillerCoors. (IBC) is involved in serving financial and operational planning, debt restructuring, investment, re-branding, business performance, revenue growth and profitability. These three powerhouses make it clear that Growpacker is starting on a solid business foundation.
And if this weren’t enough, Jon Cooper founding member of Ebbu Inc. a U.S hemp research company recently acquired by Canopy Growth Corporation for $429M USD is also a special advisor and shareholder. He brings everything research and development on the hemp platform to push the boundaries of cannabis tech.
Now if this is not a formula for success, I don’t know what is. Combining the turn key production and distribution formula with some of the most successful people in business along with a company who is far ahead of its competition, feels as comfortable a stock pick as a good old THC infused Ceria beer! Watch out Amazon, here comes Growpacker.
About Growpacker
Growpacker is a fully-licensed cannabis co-packing and bottling company that operates in California, now the worlds fifth largest economy and Americas largest consumer market. Taking a bifurcated approach on the industry, Growpacker will have the ability to manufacture products for both the regulated cannabis market (dispensaries) as well as the open market for products that are CBD only (grocery, convenience store, etc). They have proprietary THC & CBD infusion technologies, allowing them to design and manufacture the most premium cannabis-infused products on the market, including both water and oil-based products.
About Momentum PR
Momentum PR is a cutting-edge public and investor relations consulting agency, representing companies within the Canadian investment community.
Since 2009, Momentum PR has been servicing small and mid-cap Canadian-listed public companies, seeking to increase their exposure across North America. The focus at Momentum PR is on building and driving brand awareness. Momentum PR cultivates new audiences in the media and investment communities by proactively engaging interested parties on behalf of client companies, through online and offline channels.
Disclaimer:
All editorial content contained herein is solely the responsibility of Momentum PR and does not reflect, in any way, the opinions of Growpacker
—
Isabelle Arsenault
Media Relations
MomentumPR
p:+1.450.332.6939 m: +1.514.816.2611
w:www.momentumpr.com e: isabelle@momentumpr.com
- Published in Blog, Cannabis, growpacker, Marijuana, News Home, Technology
DIAGNOS Welcomes Dr. Jean-Francois Yale to the Board of Directors
Momentum Public Relations
Press Release: January 29, 2019
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the appointment of Dr. Jean-Francois Yale to its board of directors.
Dr. Yale is an endocrinologist, currently professor of medicine at the McGill University Department of Medicine. Dr. Yale chaired the Clinical and Scientific Section of the Canadian Diabetes Association from 1992-1994 as well as the Expert Committee that published the 2001 Clinical Practice Guidelines for the Prevention and Management of Diabetes. Dr. Yale’s research interests (210 publications) include the prevention of hypoglycemia in type 1 diabetes and he participated in numerous multicentre trials on new therapies for type 1 and type 2 diabetes.
“We are delighted to have Dr. Yale joining the Board. I am convinced that DIAGNOS will greatly benefit from his specialized interest in intensive management of type 1 and type 2 diabetes,” said Mr. Georges Hebert, Chairman of the board of directors of DIAGNOS.
The board of directors has approved a grant of 2,620,000 stock options to the directors and officers of the Corporation. Stock options vest at 50% per year, commencing with the first anniversary of the grant. The exercise price of these options has been established at $0.05 per share. The expiry date to which these options can be exercised has been fixed to January 28, 2024.
All monies quoted in this press release shall be stated and paid in lawful money of Canada.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information is available at www.diagnos.com and www.sedar.com
- Published in Diagnos, Life Sciences, News Home, Technology
Mondias announces agreement with Wisdom of Nature Brokerage to expand retail sales in Ontario and grants stock options
Momentum Public Relations
Press Release: January 25, 2019
Mondias Natural Products Inc (“Mondias” or “Company“), (TSX VENTURE: NHP) announces the signing of a sales representation agreement with Wisdom of Nature Brokerage, a company specializing in the retail sales of Natural Health Products in Ontario. Mondias through its recently acquired Holizen brand, has been operating successfully in the province of Quebec and is now expanding retail operations to Ontario for the first phase of its Canada wide distribution.
Other news
The Board of Directors of the Company has approved the granting of 2,550,000 stock options to directors, officers, consultants and employees of the Company. The exercise price of the options is $0.235 (the closing price of the shares on January 21, 2019). The options vest over a 3-year period.
The above-mentioned options have been granted pursuant to the Mondias’s Stock Option Plan. Following this stock option grant the Company has a total of 2,950,804 stock options outstanding, which represents less than 5% of the Company’s issued and outstanding common shares.
About Wisdom of Nature Inc.
With more than 25 years of experience in the Natural Health Food Industry, Wisdom of Nature, led by its president and CEO Corine Johnson, specializes in sales development and independent/mass market product listing across the province of Ontario. They represent top brands like Strauss, Joy of the Mountain, Nature’s Aid, Abundance Naturally, Cannanda and Pro Santé.
About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence based botanical products for the health care and bio agriculture markets. The company is already selling both oral and topical botanical agents to help manage unmet medical needs through Holizen Laboratories, one of its divisions. Mondias is also developing botanical based specialty fertilizers for use on household plants, urban gardens, lawns, golf courses, nurseries or greenhouses in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit : mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Life Sciences, Mondias Natural, News Home, Technology